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E V I D E N C E - B A S E D A N S W E R
There is adequate evidence for screening
neonates for hemoglobinopathies, congeni-
tal hypothyroidism, phenylketonuria (strength
of recommendation [SOR]: A), and cystic
fibrosis (SOR: B). Vision screening should be
done for those younger than age 5 years
(SOR: B). High-risk children should be test-
ed for tuberculosis (TB) (SOR: B) and lead
toxicity (SOR: B). Few data exist to guide 
frequency and timing of these screening
tests, so the following timing recommenda-
tions are based on consensus opinion
(SOR: C): test for visual acuity yearly starting
at age 3 years; test for TB and lead once
between the ages of 9 and 12 months, and
repeat for high risk or exposure.
Obtain family history; order additional
screening tests if history suggests them
Why do states differ so much in the neo-
natal screening tests that they routinely
perform? Some states screen for only a
few genetic diseases, others for more than
40. Most states do neonatal hearing
screening despite limited evidence of utility,
while only one quarter of all states have
neonatal cystic fibrosis screening pro-
grams, a condition for which there is prob-
ably better evidence for screening. While
we might like to think that good science
alone would dictate screening policy, the
economic circumstances of each state,
variable interpretation/quality of the
research reviewed, and legislative priorities
(among many reasons) probably play at
least as much a roll. For any test, its accu-
racy is only as good as the pretest proba-
bility of the disease for which it is being
used. Our yield for cystic fibrosis screening
will be higher in families with a history of
cystic fibrosis. This is the key point—you
still need to obtain a family history and
order additional screening tests if the 
history suggests them.
Vince WinklerPrins, MD, FAAFP
Michigan State University, East Lansing
C L I N I C A L C O M M E N TA R Y
z Evidence summary
There are many opinions and recommen-
dations about what constitutes quality
health surveillance for children. However,
many screening tests for children lack evi-
dence of effectiveness and information on
harms.1 The scope of this question required
use of evidence published in high-quality
systematic reviews. The US Preventive
Services Task Force (USPSTF) provides the
most rigorous evidence on which to base
recommendations.2 Medline was searched
for any additional individual studies of
interest. The USPSTF has conducted
reviews for selected screening tests for chil-
dren; the TABLE summarizes those with
sufficient evidence to recommend them.
We identified 1 additional evidence-based
recommendation from the Centers for
Disease Control and Prevention. This
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report, based on a systematic review, rec-
ommends cystic fibrosis screening in
neonates based on moderate benefits and
low risks of harm.3
The TABLE summarizes the evidence
supporting universal childhood screening
for hemoglobinopathies, congenital hypo-
thyroidism, phenylketonuria, and visual
defects; and high-risk childhood screening
for tuberculosis and lead toxicity. The
TABLE also lists the recommendations from
the American Academy of Pediatrics
(AAP) on frequency and timing of screen-
ing as guided by consensus opinion.
The USPSTF recommendations sup-
porting screening for hemoglobinopathies,
congenital hypothyroidism, and phenyl-
ketonuria are considered standard of care.
The USPSTF believes that updating these
1996 recommendations would have little
impact on clinical practice. 
The USPSTF recommendations sup-
porting vision screening found no direct
evidence supporting screening for visual
TA B L E
TEST (SOR) POPULATION USPSTF COMMENTS AAFP AAP
UNIVERSAL SCREENING
Neonatal Newborns Strongly recommends Recommends once
hemoglobinopathy (A) at 2 to 4 days of life,
but before age 1 month
Neonatal Newborns—repeat at Strongly recommends
phenylketonuria (A) 2 weeks if <24 hrs old 
at discharge
Congenital Newborns Strongly recommends
hypothyroidism (A)
Vision screening for Before age 5 Type of screening tests Recommends Start objective testing
strabismus, amblyopia, vary with age; evidence yearly at age 3
and refractive error (B) inadequate to recommend 
specific test 
HIGH-RISK SCREENING
PPD test for Children at high-risk Risks for TB: HIV, close Strongly recommends Screen high-risk
tuberculosis (A) for TB contacts of persons with TB, screening high-risk children at 12 months
immigrants from countries children and or upon recognition
with high TB prevalence, of high-risk factors
low income populations,
and residents of long-term 
care facilities
Lead toxicity (B)* Infants at risk at 12 Risks for lead† Screen infants Screen high-risk
months of age at risk at high risk infants at 9 to 12
for lead exposure months. Repeat at age 
24 months for those 
at high-risk
* This document is currently being updated; the recommendation may or may not change.
† Risk are living in a house older than 1950 with peeling paint or remodeling, living near heavy traffic or lead industry, living with someone who has elevated
lead levels or whose job/hobby involves lead exposure, using lead-based pottery, or taking remedies that contain lead.
AAFP: American Academy of Family Practice recommendations from: www.aafp.org/PreBuilt/RCPS_August2005.pdf.
AAP: American Academy of Pediatrics recommendations from: aappolicy.aappublications.org/cgi/content/full/pediatrics;105/3/645.
US Preventive Services Task Force evidence-supported testing for children
acuity. One fair-quality controlled study
(N=3490) showed a decreased prevalence
of amblyopia in the screened group and
evidence that treatment of amblyotic risk
factors prevents amblyopia. A Cochrane
review of this topic showed insufficient
evidence for visual screening of older
(school-aged) children; for amblyopia, no
data sufficient for analysis was found.4,5
The USPSTF recommendation to
screen asymptomatic high-risk children for
TB is based on the effectiveness of early
intervention (14 controlled trials) and the
accuracy of the Mantoux test. 
The USPSTF document on screening
for lead levels is currently being revised
and the recommendation may change.
Although no controlled studies directly
show that screening high-risk children for
lead exposure improves clinical outcomes,
several lesser-quality studies create a logi-
cal path to this conclusion.
The USPSTF finds there is insufficient
evidence to recommend for or against per-
forming the following screening tests in
children: blood pressure screening; screen-
ing for overweight in children and adoles-
cents; and iron deficiency screening in
asymptomatic infants. Both Cochrane
Systematic Reviews and USPSTF found
insufficient evidence to support universal
hearing screening, including neonatal hear-
ing screening.6 The USPSTF makes no rec-
ommendation regarding screening high-
risk children for hyperlipidemia. 
The USPSTF recommends that the fol-
lowing tests should not be performed in
children because there is good evidence
that the harms outweigh the benefits: 
thyroid cancer screening in children and
bacteriuria screening in asymptomatic
nonpregnant children.
Recommendations from others
There are numerous guidelines recom-
mending various sets of preventive services
for children, but there are few evidence-
based recommendations. The AAP recom-
mendations can be found in Guidelines for
Health Supervision III.7 The AAP also
publishes policy statements and guidelines
in the journal Pediatrics. The American
Academy of Family Practice’s (AAFP) rec-
ommendations on health supervision can
be found at: www.aafp.org/PreBuilt/
RCPS_August2005.pdf. 
A summary of the AAFP and the AAP
recommendations on each of the USPSTF
supported tests is in the TABLE. While
AAFP and USPSTF recommendations con-
cur, AAP recommendations differ in rec-
ommending hearing screening for all new-
borns, iron deficiency screening at 9
months of age, screening for lipid disorders
in children at risk starting at 24 months,
and screening urinalysis at age 5 years. 
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